Tissue Source Site (TSS) Name: ______ TSS Identifier: ______ TSS Unique Patient #: _____

V4.40

Completed By: ___

_____ Completion Date (MM/DD/YYYY): ____

Form Notes: Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address. The following information to be provided by a pathologist


s must be recorded nated throughout "yes" in the box to n with the date of iopsy or resection) ave received e time intervals as a this form.
e for the diffuse sample being ponent > 10% are not
dicate the mponent within ma sample that t. is greater than 10%,
submitted to TCGA ant biospecimen.
dicate the nodal or hich the tissue inated.



Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
		Mediastinal Soft Tissue Pleura (Pleural Effusion) (including thymus)	
		Other Extranodal Site (please specify)	
6	Other Anatomic Site of Frozen Biospecimen		3320289 If the extranodal tumor site from which the tissue being submitted to TCGA originated is not included in the provided list, specify the other anatomic site for the tissue being submitted.
Date of Samp	le Procurement		anatomic site for the tissue being submitted.
7	Date of Sample Procurement	Month Day Year	3008197 (Month), 3008195 (Day), 3008199 (Year) Provide the date of the procedure performed to obtain the malignant tissue submitted for TCGA. 3288495
8	Number of Days from Date of Initial Pathologic Diagnosis to Date of Cancer Sample Procurement		Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of the procedure that produced the malignant sample submitted for TCGA. Note: Only provide interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.
9*	Method of Cancer Sample Procurement	□ Incisional Biopsy □ Core Biopsy □ Excisional Biopsy □ Other Method (please specify)	3103514 Indicate the procedure performed to obtain the malignant tissue submitted for TCGA. 2006730
10	Other Method of Cancer Sample Procurement		If the procedure performed to obtain the malignant tissue is not included in the provided list, specify the procedure.
11*	Country of Cancer Sample Procurement		3203072 Provide the country where the tissue submitted for TCGA was procured.
12*	Race	 American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. Asian A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. White	2192199 Provide the patient's race using the defined categories. 2192217 Provide the patient's ethnicity using the defined categories
13	Ethnicity	 Hispanic or Latino A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Evaluated: Not provided or available. Unknown: Could not be determined or unsure. 	categories.
14*	Vessel Used	 Cryovial Cryomold Cassette Biospecimen Storage Bag Other vessel (<i>please specify below</i>) 	3081940 Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR) for TCGA. 3288137
15	Other Vessel Used		If the vessel used to ship tissue to the Biospecimen Core Resource (BCR) is not included in the provided list, specify the other type of vessel used.



Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
16*	Is tumor sample being submitted for	□ Yes □ No	3521908 Indicate whether the tumor sample submitted to the BCR is intended to undergo macrodissection
17*	macrodissection? Was sample prescreened at site?	□ Yes □ No	after the BCR receives the sample. 3081942 Indicate whether the sample submitted to the
18*	Will Top Slide be submitted to the BCR?	□ Yes □ No	BCR was prescreened at the TSS. 3081944 Indicate whether a physical top slide for the sample submitted to the BCR will be shipped with the tumor tissue sample. Note: Top slide definition: Slide cut directly from
19*	Will Digital Slide Image be submitted to the BCR?	□ Yes □ No	frozen biospecimen = mirror image of inked surface. 3081948 Indicate whether a digital slide image for the sample submitted to the BCR will be shipped with the tissue sample. Physical top slides are preferred.
20*	Will a FFPE Tumor slide be submitted to the BCR?	□ Yes □ No	3295811 Indicate whether the diagnostic Formalin Fixed Paraffin Embedded (FFPE) slide representative of the patient's overall tumor is being shipped to the BCR with the tissue sample for TCGA.
21	FFPE Tumor Slide/Digital Image ID #		3295810 Provide the slide ID for the FFPE physical slide OR the digital image being sent to the BCR.
22	Will a B-Cell Tumor slide (CD20 Slide) be submitted to the BCR?	□ Yes □ No	3320292 Indicate whether a B-cell (CD20) slide representative of the patient's overall tumor is being shipped to the BCR with the tissue sample for TCGA. Note: B-cell (CD20) tumor slide is not required if the results of the slide review are documented in the pathology report, immunohistochemistry (IHC) report, or flow cytometry report.
23	B-cell Tumor Slide (CD20 Slide)/Digital Image ID #		3320294 Provide the slide ID for the B-cell (CD20) physical slide OR the digital image being sent to the BCR. 3320295
24	Will a T-Cell Tumor slide (CD3 Slide) be submitted to the BCR?	□ Yes □ No	Indicate whether a T-cell (CD3) slide representative of the patient's overall tumor is being shipped to the BCR with the tissue sample for TCGA. Note: T-cell (CD3) tumor slide is not required if the results of the slide review are documented in the pathology report, immunohistochemistry (IHC) report,
25	T-cell Tumor Slide (CD3 Slide)/Digital Image ID #		or flow cytometry report. 3320296 Provide the slide ID for the T-cell (CD3) physical slide OR the digital image being sent to the BCR.
26	Will a Flow Cytometry Report Submitted?	□ Yes □ No	3297384 Indicate whether the Flow Cytometry report is being submitted to the BCR. Note: If submitting a copy of this report, this report should be uploaded with the pathology report.
27*	Tumor Identifier		3288096 Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor needs a unique ID.
28*	Weight of Frozen Tumor	(0.2cm3 (0.6cm * 0.6cm * 0.6cm) = ~200mg	3081946 Provide the weight of the tumor sample submitted for TCGA.
29*	Tumor Nuclei %		2841225 Provide the percent of tumor nuclei for the sample submitted for TCGA. <i>Check with the BCR to</i> <i>confirm the current acceptable TCGA metrics.</i>
30*	Tumor Necrosis %		2841237 Provide the percent of necrosis for the sample submitted for TCGA. <i>Check with the BCR to confirm</i> <i>the current acceptable TCGA metrics.</i>



V4.40



Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
			3288185
45	Extracted DNA Quantity		If the normal control type is extracted DNA from
			blood, provide the quantity (μ g) of the normal
			control sample sent to the BCR for TCGA. 3288186
	Extracted DNA		If the normal control type is extracted DNA from
46			blood, provide the quantification method of the
	Quantification Method		normal control sample sent to the BCR for TCGA.
			3288187
	Extracted DNA		If the normal control type is extracted DNA from
47	Concentration		blood, provide the concentration ($\mu g/\mu L$) of the
			normal control sample sent to the BCR for TCGA.
			3288188
48	Extracted DNA Volume		If the normal control type is extracted DNA from
40	Extracted DIVA Volume		blood, provide the volume (μ L) of the normal
			control sample sent to the BCR for TCGA.
Normal Contr	ol: Normal Tissue	1	22224 47
40	Method of Normal	Incisional Biopsy Core Biopsy	3288147
49	Sample Procurement	Excisional Biopsy Other Method (specify)	Indicate the procedure performed to obtain the normal sample submitted for TCGA.
			3288151
	Other Method of Normal		If the procedure performed to obtain the normal
50	Sample Procurement		sample is not included in the provided list,
			specify the procedure.
	Data a f Na sua l Casa da		3288195 (Month), 3288196 (Day), 3288197 (Year)
51	Date of Normal Sample		Provide the date of the procedure performed to
	Procurement	Month Day Year	obtain the normal control submitted for TCGA.
			3288496
	Number of Dave from		Provide the number of days from the date the
	Number of Days from Date of Initial		patient was diagnosed with the disease
52	Pathological Diagnosis to	days	described on this form to the date of the
52	Normal Sample	uays	procedure that produced the normal control
	Procurement		sample submitted for TCGA. Note: Only provide interval data if you have received
			permission from the NCI to provide time intervals as a
			substitute for requested dates on this form.
			3288138
53	Normal Identifier		Provide the TSS unique normal ID. If multiple
			normal control samples are submitted, each
	Other Anatomic Site of		normal control needs a unique ID.
54			3288189 If the normal control type is normal tissue
54	Non-Neoplastic Control Tissue		specify the site of the non-neoplastic control.
	115500		3288217
	Normal Slide ID #		If the normal control type is normal tissue,
55			provide the slide ID for the physical top slide OR
			the digital slide image of the normal control
			being sent to the BCR.
Verification B	y providing the information below	u, the Principal Investigator acknowledges that the information provided by the institutio	
			3288225
56*	Name of Pathologist		Provide the name of the Pathologist that
	Nume of Fathologist		reviewed the top slide and provided the
			information for all previous sections. 3288224
57	Date of Pathologist Review (MM/DD/YYYY)		Provide the date of the pathology review
57			performed by the TSS pathologist above.
			3288497
			Provide the number of days from the date the
	Number of Days from		patient was initially diagnosed pathologically
	Date of Initial Pathologic		with the disease described on this form to the
58	Diagnosis to Date of		date of the pathological review performed as
	Pathological Review		part of the submission process for TCGA.
			Only provide interval data if you have received permission from
			the NCI to provide time intervals as a substitute for requested dates on this form.
			3288520
	Tumor Nuclei meets	T Yes	Confirm that the malignant sample submitted to
59*	TCGA metrics	-	the BCR meets the current tumor nuclei metrics
		L No	for TCGA. Check with the BCR to confirm the current
1			acceptable TCGA metrics.



Question #	Data Element Label	Data Entry Alternatives	CDE ID With Working Instructions
60*	Tumor Necrosis meets TCGA metrics	Yes No	3288524 Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics for TCGA. Check with the BCR to confirm the current acceptable TCGA metrics. 3288292
61*	De-Identified Pathology Report Submitted?	☐ Yes ☐ No	Confirm that a de-identified pathology report will be sent to BCR prior to or with the shipment of the physical samples. Note: For lymphoma patient, the report documenting the results of the B and T-cell markers (i.e. immunohistochemistry (IHC) and/or Flow Cytometry should be included with the copy of the pathology report.
62*	Is the histologic diagnosis on the CQCF (as determined by the TSS pathology review of the TCGA frozen section top slide) consistent with the histology listed in the final diagnosis on the pathology report?	 Yes (skip related question below.) No (See note at right) 	 3288300 Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR. Note: The diagnosis is considered to be consistent if at least one of the following criteria are met: Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR. Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR. Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR. Diagnosis on the CQCF is "histology, NOS" (i.e. Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histological group. Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable subtypes, provided that percent subtype(s) meet applicable TCGA disease-specific requirements.
63	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	 Macrodissection performed at TSS to select for a region containing an acceptable TCGA diagnosis. Pathology analysis at TSS determined a specific histological subtype different from original path report (see note at right) Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) 	3288315 If the diagnosis provided on this form is not consistent with the diagnosis found on the patient's pathology report for the tumor being submitted for TCGA, specify a reason for this inconsistency. Note: If a TSS pathology review of the TCGA committed sample resulted in a different histological subtype than what is documented on the pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; or in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "TCGA Pathologic Diagnosis Discrepancy Form." In the case of diagnosis modifications, institution protocol should be followed for proper quality assurance
64*	History of Neo-Adjuvant Treatment to Tumor Specimen Submitted for TCGA	 No Radiation Prior to Sample Procurement Pharmaceutical Treatment Prior to Sample Procurement Both Pharmaceutical and Radiation Treatment Prior to Sample Procurement 	3382737 Indicate whether the patient received therapy for this cancer prior to sample procurement of the tumor submitted for TCGA. If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instructions. Note: Systemic treatment and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to procurement of the sample submitted for TCGA are exclusionary.
65*	Has the Patient Had Any Prior Cancer Diagnosed?	 No History of Prior Malignancy History of Synchronous / Bilateral Malignancy 	3382736 Indicate whether the patient has a history of prior malignancies. Note 1: If this question cannot be answered because the answer is unknown, the case will be excluded from TCGA. Note 2: If the patient has any history of prior



0	Data Flavora data bat				
Question #	Data Element Label	Data Entry Alternative	!S		CDE ID With Working Instructions malignancies, including synchronous or bilateral
					malignancies, please complete an "Other Malignancy
					Form" for each malignancy diagnosed prior to the
					procurement of the tissue submitted for TCGA. If the
					patient has a history of multiple diagnoses of basal
					and/or squamous cell skin cancers, complete an "Other
					Malignancy Form" for the first diagnosis for each of these types.
				_	2180464
	Is Patient HIV Positive (+)?	Positive		Not Evaluated	Indicate whether the patient is HIV positive (+)
66*			Г	1	or negative (-).
		└── Negative		Unknown	Note: If patient is HIV+, this is an exclusionary criterion.
					3288361
			Г	1	Indicate whether the patient was formally
67*	Consent Status	Consented	L	Exemption 4	consented, consented by death, or if the case
-		Deceased		Waiver	has an exemption or waiver for consent.
					Note: If the patient formally consented, only supply the
Date of Conse		Note: Do not answer th	his question if t	he patient consented by death o	date of patient consent.
Date of conse			ins question if th	le patient consented by death of	3081955 (Month), 3081957 (Day), 3081959 (Year)
68	Date of Consent				If the patient was formally consented, provide
		Month Day		Year	the date of consent.
					3288498
					If the patient formally consented, provide the
	Number of Days from				number of days from the date the patient was
60	, Date of Initial Pathologic				initially diagnosed pathologically with the
69	Diagnosis to Date of Consent				disease described on this form to the date of the
					patient's formal consent.
					Note: Only provide interval data if you have received permission from the NCI to provide time intervals as a
					substitute for requested dates on this form.
Date of Death	1	Note: If the patient for	mally consente	ed, only provide the date of patie	
					2897026 (Month), 2897028 (Day), 2897030 (Year)
70	Date of Death				If the patient consented by death, provide the
		Month Day		Year	date of death.
					3288499
	Number of Days from Date of Initial Pathologic Diagnosis to Date of Death				If the patient consented by death, provide the
					number of days from the date the patient was
					initially diagnosed pathologically with the disease described on this form to the date of the
					patient's death.
71					Note 1: If the patient formally consented prior to death,
					do not answer this question only answer the question
	Death				above that asks for the number of days between the
					date of diagnosis and the date of the patient consent. Note 2: Only provide interval data if you have received
					permission from the NCI to provide time intervals as a
					substitute for requested dates on this form.
Comments					

Principal Investigator Name: ______ Principal Investigator Signature: ______

Date Signed (MM/DD/YYYY):